Cullinan Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
2.3%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$13.9Mnext fiscal year
FY EPS (est.)
-$3.17next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| CLN-049 Phase 1 Dose Escalation Update in R/R AML/MDS | 31 Dec 2026 |
| Taiho Oncology REZILIENT3 Frontline NSCLC Top-Line Results | 31 Dec 2026 |
| Zipalertinib FDA PDUFA Target Action Date | 27 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, short- and long-term investments, and interest receivable Quarterly393.3MTarget: Sufficient to fund operations into 2029
Research and Development (R&D) Expenses Quarterly42.1MTarget: Disciplined clinical-stage pipeline investment
CLN-978 OUTRACE Phase 1 Patient Enrollment Quarterly42.0Target: Complete dose escalation and expand cohorts
Watch Items
- CLN-978 Cytokine Release Syndrome (CRS) and Safety ProfileTrigger: Any Grade 3 or higher CRS events (such as the one observed at the 45 µg dose level)Action: Discontinue enrollment in high-dose cohorts, implement step-up dosing regimens, and focus on outpatient-compatible subcutaneous doses (10-30 µg).
- Zipalertinib FDA Approval Status (PDUFA Target Action Date)Trigger: FDA decision on or before February 27, 2027Action: Coordinate with partner Taiho Oncology to prepare for commercial launch and secure the $30 million second-line regulatory milestone payment.
- CLN-049 Recommended Phase 2 Dose (RP2D) DeterminationTrigger: Determination of RP2D by Q4 2026Action: Initiate a single-arm pivotal registrational trial in relapsed/refractory AML or MDS and launch a Phase 1/2 frontline combination study.
Research as of 19 Jun 2026